Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell secretions vs. PRP: which injection grows more hair?

NCT ID NCT07429253

Disease control Sponsor: PT. Prodia Stem Cell Indonesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether injections of secretome (a substance made by stem cells) or platelet-rich plasma (PRP) can improve hair density and thickness in people with androgenetic alopecia (common baldness). Forty men and women with mild to moderate hair loss will receive injections every two weeks for eight weeks. The goal is to see which treatment works better for regrowing hair.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secretome (stem cell byproducts) and Platelet-Rich Plasma (PRP) injections
What this could lead to
If it works, this could point toward a new, non-surgical treatment for common hair loss using stem cell secretions.
What could go wrong
This is a very small, early-phase trial (40 people) comparing two experimental injections. Results may not apply to everyone, and long-term safety or effectiveness is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients who are not currently pregnant or breastfeeding. * Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure. * Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * Patients who are proficient in Indonesian and willing to provide written informed consent. Exclusion Criteria: * Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent. * Patients presenting with types of hair loss other than androgenetic alopecia. * Patients currently undergoing therapy with 5-alpha reductase inhibitors. * Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study. * Patients with active infections and/or active dermatitis on the scalp. * Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * History of hypertrophic scarring or blood clotting (coagulation) disorders. * Patients unable to complete the research procedures in their entirety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prof. dr. I.G.N.G. Ngoerah Central General Hospital

    RECRUITING

    Denpasar, Bali, 80113, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.